Amendments to the Claims:

This listing of claims will replace all prior version, and listing, of claims in the application.

Listing of Claims:

1. (currently amended): ~~An acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amine according to the general~~ A compound of formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof



(I)

wherein

R^1 and R^4 are independently from each other ~~selected~~ chosen from ~~the group consisting of~~:

H; unsubstituted and at least monosubstituted C_1-C_{10}-alkyl, C_2-C_{10}-alkenyl and C_2-C_{10}-alkynyl, the substituents of which are ~~selected~~chosen from ~~the group consisting of~~ F, OH, C_1-C_8-alkoxy, (C_1-C_8-alkyl)mercapto, CN, $COOR^6$, $CONR^7R^8$, and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are ~~selected~~chosen from ~~the group consisting of~~ halogens, pseudohalogens, C_1-C_3-alkyl, C_1-C_3-alkoxy and CF_3; unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are ~~selected~~chosen from ~~the group consisting of~~ halogens, pseudohalogens, C_1-C_3-alkyl, C_1-C_3-alkoxy and CF_3; R^9CO; $CONR^{10}R^{11}$;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

$COOR^{12}$; CF_3; halogens; pseudohalogens; $NR^{13}R^{14}$; OR^{15}; $S(O)_mR^{16}$; $SO_2NR^{17}R^{18}$; and NO_2;

R^2 and R^3 are independently from each other ~~selected~~ chosen from ~~the group consisting of~~:

H; halogens; pseudohalogens; unsubstituted and at least monosubstituted C_1-C_{10}-alkyl, the substituents of which are ~~selected~~ chosen from ~~the group consisting of~~ OH, phenyl, and heteroaryl; OH; C_1-C_{10}-alkoxy; phenoxy; $S(O)_mR^{19}$; CF_3; CN; NO_2; (C_1-C_{10}-alkyl)amino; di(C_1-C_{10}-alkyl)amino; (C_1-C_6-alkyl)-CONH-; unsubstituted and at least monosubstituted phenyl-CONH- and phenyl-SO_2-O-, the substituents of which are ~~selected~~chosen from ~~the group consisting of~~ halogens, pseudohalogens, CH_3 and methoxy; (C_1-C_6-alkyl)SO_2-O-; unsubstituted and at least monosubstituted (C_1-C_6-alkyl)CO, the substituents of which are ~~selected~~chosen from ~~the group consisting of~~ F, di(C_1-C_3-alkyl)amino, pyrrolidinyl and piperidinyl; and phenyl-CO, the phenyl part of which can be substituted by one or more substituents chosen from ~~the group consisting of~~ C_1-C_3-alkyl, halogens and methoxy;

A is ~~selected~~ chosen from ~~the group consisting of~~ CH_2, CHOH and CH-(C_1-C_3-alkyl);

B is ~~selected~~ chosen from ~~the group consisting of~~ CH_2 and CH-(C_1-C_3-alkyl);

C independently has the same meaning as B;

D independently has the same meaning as B;

R^5 is a group Ar or a group Hetar both of which can be unsubstituted or carry one or more substituents ~~selected~~ chosen from ~~the group consisting of~~: halogens; pseudohalogens; NH_2; unsubstituted and at least monosubstituted C_1-C_{10}-alkyl,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

C_2-C_{10}-alkenyl, C_2-C_{10}-alkynyl, C_1-C_{10}-alkoxy, (C_1-C_{10}-alkyl)amino, and di(C_1-C_{10}-alkyl)amino, the substituents of which are ~~selected~~ chosen from ~~the group consisting of~~ F, OH, C_1-C_8-alkoxy, aryloxy, (C_1-C_8-alkyl)mercapto, NH_2, (C_1-C_8-alkyl)amino, and di(C_1-C_8-alkyl)amino; C_3-C_5-alkandiyl; phenyl; heteroaryl; aryl- or heteroaryl-substituted C_1-C_4-alkyl; CF_3; NO_2; OH; phenoxy; benzyloxy; (C_1-C_{10}-alkyl)COO; $S(O)_mR^{20}$; SH; phenylamino; benzylamino; (C_1-C_{10}-alkyl)-CONH-; (C_1-C_{10}-alkyl)-CON(C_1-C_4-alkyl)-; phenyl-CONH-; phenyl-CON(C_1-C_4-alkyl)-; heteroaryl-CONH-; heteroaryl-CON(C_1-C_4-alkyl)-; (C_1-C_{10}-alkyl)-CO; phenyl-CO; heteroaryl-CO; CF_3-CO; -OCH_2O-; -OCF_2O-; -OCH_2CH_2O-; -CH_2CH_2O-; $COOR^{21}$; $CONR^{22}R^{23}$; $CNH(NH_2)$; $SO_2NR^{24}R^{25}$; $R^{26}O_2NH$-; $R^{27}SO_2N(C_1$-C_6-alkyl)-; and saturated and at least monounsaturated aliphatic, mononuclear 5- to 7-membered heterocycles containing 1 to 3 heteroatoms ~~selected~~ chosen from ~~the group consisting of~~ N, O, and S, which heterocycles can be substituted by one or more substituents ~~selected~~chosen from ~~the group consisting of~~ halogens, C_1-C_3-alkyl, C_1-C_3-alkoxy, OH, oxo and CF_3, and wherein said heterocycles can optionally be condensed to ~~the~~ said group Ar or ~~the~~ said group Hetar; and wherein all aryl, heteroaryl, phenyl, aryl-containing, heteroaryl-containing and phenyl-containing groups, which are optionally present in ~~the~~ said substituents of ~~the~~ said group Ar or ~~the~~ said group Hetar, can be substituted by one or more substituents ~~selected~~ chosen from ~~the group consisting of~~ halogens, pseudohalogens, C_1-C_3-alkyl, OH, C_1-C_3-alkoxy, and CF_3;

R^6 is ~~selected~~ chosen from ~~the group consisting of~~:

H; C_1-C_{10}-alkyl, which can be substituted by one or more substituents ~~selected~~chosen from ~~the group consisting of~~ F, C_1-C_8-alkoxy, and di(C_1-C_8-alkyl)amino;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

aryl-(C_1-C_4-alkyl) and heteroaryl-(C_1-C_4-alkyl), which can be substituted by one or more substituents ~~selected~~ chosen from ~~the group consisting of~~ halogens, C_1-C_4-alkoxy, and di(C_1-C_6-alkyl)amino;

R^7 is ~~selected~~ chosen from ~~the group consisting of~~:

H; C_1-C_{10}-alkyl which can be substituted by one or more substituents ~~selected~~ chosen from ~~the group consisting of~~ F, C_1-C_8-alkoxy, di(C_1-C_8-alkyl)amino and phenyl; phenyl; indanyl; and heteroaryl; and wherein each of the aforementioned aromatic groups can be unsubstituted or carry one or more substituents chosen from ~~the group consisting of~~ halogens, pseudohalogens, C_1-C_3-alkyl, C_1-C_3-alkoxy and CF_3;

R^8 is H or C_1-C_{10}-alkyl;

R^9 is ~~selected~~chosen from ~~the group consisting of~~: C_1-C_{10}-alkyl which can be unsubstituted or carry one or more substituents chosen from ~~the group consisting of~~: F, (C_1-C_4)-alkoxy, di(C_1-C_3-alkyl)amino; and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are ~~selected~~ chosen from ~~the group consisting of~~ C_1-C_3-alkyl, C_1-C_3-alkoxy, halogens, pseudohalogens, and CF_3;

R^{10} independently has the same meaning as R^7;

R^{11} independently has the same meaning as R^8;

R^{12} independently has the same meaning as R^6;

R^{13} is ~~selected~~ chosen from ~~the group consisting of~~: H; C_1-C_6-alkyl; unsubstituted and substituted phenyl, benzyl, heteroaryl, (C_1-C_6-alkyl)-CO, phenyl-CO, and heteroaryl-CO, the substituents of which are ~~selected~~ chosen from ~~the group consisting of~~ halogens, pseudohalogens, C_1-C_3-alkyl, C_1-C_3-alkoxy, and CF_3, and wherein one or more of these substituents can be present;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

R^{14} independently has the same meaning as R^{13};

R^{15} is ~~selected~~chosen from ~~the group consisting of~~: H; C_1-C_{10}-alkyl; (C_1-C_3-alkoxy)-C_1-C_3-alkyl; and substituted and unsubstituted benzyl, phenyl and heteroaryl, the substituents of which are ~~selected~~ chosen from ~~the group consisting of~~ halogens, pseudohalogens, C_1-C_3-alkyl, C_1-C_3-alkoxy, and CF_3, and wherein one or more of these substituents can be present;

R^{16} is ~~selected~~ chosen from ~~the group consisting of~~: C_1-C_{10}-alkyl which can be substituted by one or more substituents ~~selected~~ chosen from ~~the group consisting of~~ F, OH, C_1-C_8-alkoxy, aryloxy, (C_1-C_8-alkyl)mercapto, (C_1-C_8-alkyl)amino and di(C_1-C_8-alkyl)amino; CF_3; and substituted and unsubstituted phenyl and heteroaryl, the substituents of which are ~~selected~~ chosen from ~~the group consisting of~~ halogens, pseudohalogens, C_1-C_3-alkyl, C_1-C_3-alkoxy and CF_3, and wherein one or more of these substituents can be present;

R^{17} independently has the same meaning as R^7;

R^{18} independently has the same meaning as R^8;

R^{19} independently has the same meaning as R^{16};

R^{20} independently has the same meaning as R^{16};

R^{21} independently has the same meaning as R^6;

R^{22} independently has the same meaning as R^7;

R^{23} independently has the same meaning as R^8;

R^{24} independently has the same meaning as R^7;

R^{25} independently has the same meaning as R^8;

R^{26} independently has the same meaning as R^{16};

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

R^{27} independently has the same meaning as R^{16};

heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms ~~selected~~ chosen from ~~the group consisting of~~ N, O, and S;

the group Hetar is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms ~~selected~~ chosen from ~~the group consisting of~~ N, O, and S;

aryl is phenyl, naphth- 1-y1 or naphth-2-yl;

the group Ar is phenyl, naphth-1-yl or naphth-2-yl; and

m is 0, 1 or 2.

2. (currently amended): ~~An acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amine~~The compound of formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof according to claim 1, wherein, in the formula (I),

R^1 is ~~selected~~ chosen from ~~the group consisting of~~: H; C_1-C_4-alkyl; C_1-C_4-alkoxy; CF_3; halogens; pseudohalogens; (C_1-C_4-alkyl)-$S(O)_m$-; and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are ~~selected~~chosen from ~~the group consisting of~~ halogens, pseudohalogens, C_1-C_3-alkyl, C_1-C_3-alkoxy and CF_3, and wherein heteroaryl is ~~selected~~ chosen from ~~the group consisting of~~ 5- and 6-membered heterocycles containing one or more heteroatoms chosen from ~~the group consisting of~~ N, O, and S;

R^2 and R^3 are independently from each other ~~selected~~ chosen from ~~the group consisting of~~:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

H; halogens; pseudohalogens; and C_1-C_3-alkyl;

R^4 independently has the same meaning as R^1;

A is ~~selected~~ chosen from ~~the group consisting of~~ CH_2 and CHOH;

B, C and D are independently from each other ~~selected~~ chosen from ~~the group consisting of~~ CH_2 and CH-CH_3;

R^5 is a group Ar or a group Hetar both of which can be unsubstituted or carry one or more substituents ~~selected~~chosen from ~~the group consisting of~~: halogens; CN; NH_2; unsubstituted and at least monosubstituted C_1-C_8-alkyl, C_2-C_8-alkenyl, C_2-C_8-alkynyl, C_1-C_8-alkoxy, (C_1-C_8-alkyl)amino, and di(C_1-C_8-alkyl)amino, the substituents of which are ~~selected~~ chosen from ~~the group consisting of~~ F, C_1-C_6-alkoxy, phenoxy, (C_1-C_6-alkyl)mercapto, NH_2, (C_1-C_6-alkyl)amino, and di(C_1-C_6-alkyl)amino; C_3-C_5-alkandiyl; phenyl; heteroaryl; phenyl- or heteroaryl-substituted C_1-C_2-alkyl; CF_3; OH; phenoxy; benzyloxy; (C_1-C_6-alkyl)COO; $S(O)_m$(C_1-C_6)-alkyl; $S(O)_m$-phenyl; $S(O)_m$-heteroaryl; SH; phenylamino; benzylamino; (C_1-C_6-alkyl)-CONH-; (C_1-C_6-alkyl)-CON(C_1-C_4-alkyl)-; phenyl-CONH-; phenyl-CON(C_1-C_4-alkyl)-; heteroaryl-CONH-; heteroaryl-CON(C_1-C_4-alkyl)-; (C_1-C_6-alkyl)-CO; phenyl-CO; heteroaryl-CO; CF_3-CO; -OCH_2O-; -OCF_2O-; -OCH_2CH_2O-, -CH_2CH_2O-; COO(C_1-C_6-alkyl); -$CONH_2$; -CONH(C_1-C_6-alkyl); -CON(di(C_1-C_6-alkyl)); CNH(NH_2); -SO_2NH_2; -SO_2NH(C_1-C_6-alkyl); -SO_2NH(phenyl); -SO_2N(di(C_1-C_6-alkyl)); (C_1-C_6-alkyl)SO_2NH-; (C_1-C_6-alkyl)SO_2N(C_1-C_6-alkyl)-; phenyl-SO_2NH-; phenyl-SO_2N(C_1-C_6-alkyl)-; heteroaryl-SO_2NH-; heteroaryl-SO_2N(C_1-C_6-alkyl)-; and saturated and at least monounsaturated aliphatic, mononuclear 5- to 7-membered heterocycles containing 1 to 3 heteroatoms ~~selected~~ chosen from ~~the group consisting~~

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

~~of~~ N, O, and S, which heterocycles can be substituted by one or more substituents ~~selected~~ chosen from ~~the group consisting of~~ halogens, C_1-C_3-alkyl, C_1-C_3-alkoxy, OH, oxo and CF_3, and wherein said heterocycles can optionally be condensed to ~~the~~ said group Ar or ~~the~~ said group Hetar; and wherein all heteroaryl, phenyl, heteroaryl-containing and phenyl-containing groups, which are optionally present in ~~the~~ said substituents of ~~the~~ said group Ar or ~~the~~ said group Hetar, can be substituted by one or more substituents ~~selected~~ chosen from ~~the group consisting of~~ halogens, pseudohalogens, C_1-C_3-alkyl, OH, C_1-C_3-alkoxy, and CF_3;

heteroaryl is a 5- to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms ~~selected~~ chosen from ~~the group consisting of~~ N, O, and S;

the group Hetar is a 5- to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms ~~selected~~ chosen from ~~the group consisting of~~ N, O, and S;

the group Ar is phenyl, naphth-1-yl or naphth-2-yl; and

m is 0 or 2.

3. (currently amended): ~~An acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amine~~The compound of formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof according to claim 1, wherein, in the formula (I),

R^1 is H, halogen or C_1-C_4-alkyl;

R^2 and R^3 are each H;

R^4 independently has the same meaning as R^1;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

A, B and C are each CH_2;

D is ~~selected~~ chosen from ~~the group consisting of~~ CH_2 and $CH\text{-}CH_3$;

R^5 is phenyl or a group Hetar both of which can be unsubstituted or carry one or more substituents ~~selected~~ chosen from ~~the group consisting of~~: halogens; CN; NH_2; unsubstituted and at least monosubstituted C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_3-alkoxy, (C_1-C_4-alkyl)amino, di(C_1-C_4-alkyl)amino, the substituents of which are ~~selected~~ chosen from ~~the group consisting of~~ F, C_1-C_3-alkoxy, (C_1-C_3-alkyl)mercapto, and NH_2; C_3-C_5-alkandiyl; phenyl; heteroaryl; phenyl- or heteroaryl-substituted C_1-C_2-alkyl; CF_3; OH; (C_1-C_4-alkyl)COO; $S(O)_m(C_1\text{-}C_4)$-alkyl; (C_1-C_4-alkyl)-CONH-; (C_1-C_4-alkyl)-CON(C_1-C_4-alkyl)-; (C_1-C_4-alkyl)-CO; phenyl-CO; heteroaryl-CO; CF_3-CO; $-OCH_2O-$; $-OCF_2O-$; $-OCH_2CH_2O-$; $-CH_2CH_2O-$; COO(C_1-C_6-alkyl); $-CONH_2$; -CONH(C_1-C_4-alkyl); -CON(di(C_1-C_4-alkyl)); CNH(NH_2); $-SO_2NH_2$; $-SO_2NH(C_1\text{-}C_4\text{-alkyl})$; $-SO_2NH$(phenyl); $-SO_2N$(di(C_1-C_4-alkyl)); (C_1-C_4-alkyl)SO_2NH-; (C_1-C_4-alkyl)$SO_2N(C_1\text{-}C_4$-alkyl)-; and saturated and at least monounsaturated aliphatic, mononuclear 5- to 7-membered heterocycles containing 1 to 3 heteroatoms ~~selected~~ chosen from ~~the group consisting of~~ N, O, and S, which heterocycles can be substituted by one or more substituents ~~selected~~chosen from ~~the group consisting of~~ halogens, C_1-C_3-alkyl, C_1-C_3-alkoxy, OH, oxo and CF_3, and wherein said heterocycles can optionally be condensed to ~~the~~ said phenyl or ~~the~~ said group Hetar; and wherein all heteroaryl, phenyl, heteroaryl-containing and phenyl-containing groups, which are optionally present in ~~the~~ said substituents of ~~the~~ said phenyl or ~~the~~ said group Hetar, can be substituted by one or more substituents ~~selected~~ chosen from ~~the group consisting of~~ halogens, pseudohalogens, C_1-C_3-alkyl, OH, C_1-C_3-alkoxy, and CF_3;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

heteroaryl is a 5- to 10-membered, aromatic, mono- or bicyclic heterocycle containing one, two or three heteroatoms ~~selected~~ chosen from ~~the group consisting of~~ N, O, and S;

the group Hetar is a 5- to 10-membered, aromatic, mono- or bicyclic heterocycle containing one, two or three heteroatoms ~~selected~~ chosen from ~~the group consisting of~~ N, O, and S; and

m is 0 or 2.

4. (currently amended): ~~An acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amine~~The compound of formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof according to claim 1, wherein, in the formula (I),

R^1 is H, halogen or C_1-C_4-alkyl;

R^2 and R^3 are each H;

R^4 independently has the same meaning as R^1;

A, B and C are each CH_2;

D is ~~selected~~ chosen from ~~the group consisting of~~ CH_2 and $CH\text{-}CH_3$;

R^5 is phenyl or a group Hetar both of which can be unsubstituted or carry one or more substituents ~~selected~~ chosen from ~~the group consisting of~~: F; Cl; Br; C_1-C_3-alkyl; C_1-C_3-alkoxymethyl; 2-amino-3,3,3-trifluoro-propyl-; CF_3; C_3-C_5-alkandiyl; phenyl; heteroaryl; benzyl; heteroaryl-methyl; OH; C_1-C_3-alkoxy; phenoxy; trifluoromethoxy; 2,2,2-trifluoroethoxy; (C_1-C_4-alkyl)COO; (C_1-C_3-alkyl)mercapto; phenylmercapto; (C_1-C_3-alkyl)sulfonyl; phenylsulfonyl; NH_2; (C_1-C_4-alkyl)amino; di(C_1-C_4-alkyl)amino; (C_1-C_3-alkyl)-CONH-; (C_1-C_3-alkyl)-SO_2NH-; (C_1-C_3-alkyl)-CO; phenyl-CO; -OCH_2O-;

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP
1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

-OCF_2O-; -CH_2CH_2O-; $COO(C_1$-C_4-alkyl); -$CONH_2$; -$CONH(C_1$-C_4-alkyl); -$CON(di(C_1$-C_4-alkyl)); CN; -SO_2NH_2; -$SO_2NH(C_1$-C_4-alkyl); -$SO_2N(di(C_1$-C_4-alkyl)); pyrrolidinyl; piperidinyl; morpholinyl; and thiomorpholinyl; and wherein all heteroaryl, phenyl, heteroaryl-containing and phenyl-containing groups, which are optionally present in ~~the~~ said substituents of ~~the~~ said phenyl or ~~the~~ said group Hetar, can be substituted by one or more substituents ~~selected~~ chosen from ~~the group consisting of~~ halogens, pseudohalogens, C_1-C_3-alkyl, OH, C_1-C_3-alkoxy, and CF_3;

heteroaryl is ~~selected~~ chosen from ~~the group consisting of~~: furyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridazinyl, pyrazinyl, pyridyl, pyrimidinyl, benzoimidazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolyl, indolyl, benzofuranyl, benzothiophenyl, and indazolyl; and

the group Hetar is ~~selected~~ chosen from ~~the group consisting of~~: furyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridazinyl, pyrazinyl, pyridyl, pyrimidinyl, benzoimidazolyl, benzthiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolyl, indolyl, benzofuranyl, benzothiophenyl, and indazolyl.

5. (currently amended): ~~An acylated 6,7,8,9 tetrahydro 5H benzocycloheptenyl amine~~The compound of formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof according to claim 1, wherein, in the formula (I),

R^1 is H, halogen or C_1-C_4-alkyl;

R^2 and R^3 are each H;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

R^4 independently has the same meaning as R^1;

A, B and C are each CH_2;

D is ~~selected~~ chosen from ~~the group consisting of~~ CH_2 and $CH\text{-}CH_3$; and

R^5 is ~~selected~~chosen from ~~the group consisting of~~: 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-(C_1-C_3-alkoxy)-phenyl, 4-trifluoromethoxyphenyl, 2-bromo-4-fluorophenyl, 2-chloro-4-fluorophenyl, 3,4-dimethylphenyl, 2,4-dimethylphenyl, 4-chloro-2-methylphenyl, 2-hydroxy-4-methylphenyl, 2-hydroxy-4-ethoxyphenyl, 2-methoxy-4-methylphenyl, 4-phenoxyphenyl, 3-fluoro-4-methylphenyl, benzo[1,3]dioxol-5-yl, 2,2-difluoro-benzo[1,3]dioxol-5-yl, 2,3-dihydrobenzofuran-5-yl, 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-yl, 1-(4-fluoro-phenyl)-3,5-dimethyl-1H-pyrazole-4-yl, 1H-benzotriazole-5-yl, 1H-indole-4-yl, 1H-indole-6-yl, 1-isopropyl-2-trifluoromethyl-1H-benzoimidazole-5-yl, 1-methyl-3-oxo-1,2,3,4-tetrahydro-quinoxaline-6-yl, 1-phenyl-5-trifluoromethyl-1H-pyrazole-4-yl, 2-(2-hydroxy-pyridin-4-yl)-1H-benzoimidazole-5-yl, 2-(4-cyano-phenyl)-1H-benzoimidazole-5-yl, 2,4-dimethyl-oxazole-5-yl, 2,4-dimethyl-pyrimidine-5-yl; 2,4-dimethyl-thiazole-5-yl, 2,5-dimethyl-1H-pyrrole-3-yl, 2,5-dimethyl-1-phenyl-1H-pyrrole-3-yl, 2,5-dimethyl-1-pyridin-4-ylmethyl-1H-pyrrolyl, 2,5-dimethyl-2H-pyrazole-3-yl, 2,6-dichloro-pyrid-3-yl, 2,6-dimethoxy-pyrid-3-yl, 2,6-dimethyl-pyrid-3-yl, 2-amino-4,6-dimethyl-pyrid-3-yl, 2-amino-6-chloro-pyrid-3-yl, 2-amino-pyrid-3-yl, 2-chloro-6-methyl-pyrid-3-yl, 2-chloro-pyrid-4-yl, 2-cyclopropyl-4-methyl-thiazole-5-yl, 2-dimethylamino-4-methyl-thiazole-5-yl, 2-dimethylamino-pyrid-4-yl, 2-ethyl-5-methyl-2H-pyrazole-3-yl, 2-hydroxy-6-methyl-pyrid-3-yl, 2-methyl-1H-benzoimidazole-5-yl, 2-methyl-3H-benzoimidazole-5-yl, 2-methyl-pyrid-3-yl, 2-methyl-6-trifluoromethyl-pyrid-3-yl,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

2-methyl-thiazole-5-yl, 2-morpholin-4-yl-pyridin-4-yl, 2-morpholin-4-yl-pyrimidine-5-yl, 2-pyrrolidin-1-yl-pyridin-4-yl, 3,5-dimethyl-1H-pyrazole-4-yl, 3-amino-5,6-dimethyl-pyrazine-2-yl, 3-amino-5-methyl-pyrazine-2-yl, 3-amino-pyrazine-2-yl, 3-dimethylamino-4-methyl-phenyl, 3-dimethylamino-phenyl, 3H-benzoimidazole-5-yl, 1H-benzoimidazole-5-yl, 3-methanesulfonylamino-2-methyl-phenyl, 3-methanesulfonylamino-phenyl, 3-methyl-isoxazole-4-yl, 3-morpholin-4-yl-phenyl, 3-piperidin-1-yl-phenyl, 3-pyrrolidin-1-yl-phenyl, 4-(2,2,2-trifluoro-ethoxy)-phenyl, 4,6-dimethyl-pyrid-3-yl, 4-amino-2-ethylsulfanyl-pyrimidine-5-yl, 4-amino-2-methyl-pyrimidine-5-yl, 4-chloro-3-methanesulfonylamino-phenyl, 4-chloro-3-sulfamoyl-phenyl, 4-methyl-3-methylamino-phenyl, 4-methyl-thiazole-5-yl, pyridine-2-yl, 5,6,7,8-tetrahydro-quinoline-3-yl, 5-amino-1-phenyl-1H-pyrazole-4-yl, 5-methanesulfonyl-2-methyl-phenyl, 5-methyl-1-phenyl-1H-pyrazole-4-yl, 5-methyl-isoxazole-3-yl, 5-methyl-pyrid-3-yl, 5-methyl-pyrazine-2-yl, 6-chloro-pyrid-3-yl, 6-cyano-pyrid-3-yl, 6-dimethylamino-pyrid-3-yl, 6-ethynyl-pyrid-3-yl, 6-methoxymethyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl, 6-methyl-2-methylamino-pyrid-3-yl, 6-methylamino-pyrazine-2-yl, 6-methyl-pyrid-3-yl, 6-morpholin-4-yl-pyrid-3-yl, 6-pyrrolidin-1-yl-pyrid-3-yl, imidazo[1,2-a]pyridine-2-yl, 6-trifluoromethyl-pyrid-3-yl, and pyrimidine-4-yl.

6. (currently amended): ~~An acylated 6,7,8,9 tetrahydro 5H-benzocycloheptenyl amine~~The compound of formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof according to claim 1, ~~selected~~ chosen from ~~the group consisting of~~:

2,5-dimethyl-1-pyridin-4-ylmethyl-1H-pyrrole-3-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, 5-methyl-1-phenyl-1H-pyrazole-4-

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, 1H-indole-6-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, 5-methyl-pyrazine-2-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, 2-methyl-3H-benzoimidazole-5-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, 2-methyl-1H-benzoimidazole-5-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, 2-amino-6-chloro-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-nicotinamide, N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-4-(2,2,2-trifluoro-ethoxy)-benzamide, 6-pyrrolidin-1-yl-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-nicotinamide, 6-methyl-2-methylamino-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-nicotinamide, 3-amino-5,6-dimethyl-pyrazine-2-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, 4-fluoro-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-benzamide, 3-pyrrolidin-1-yl-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-benzamide, 2,4-dimethyl-thiazole-5-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, 2-amino-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-nicotinamide, 2,6-dimethyl-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-nicotinamide, 3-amino-5-methyl-pyrazine-2-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, and 3-amino-pyrazine-2-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide.

7. (withdrawn): A method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering to said mammal a physiologically active amount of a compound as defined in claim 1 in any of its

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

8. (withdrawn): A method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering to said mammal a physiologically active amount of a compound as defined in claim 2 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

9. (withdrawn): A method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering to said mammal a physiologically active amount of a compound as defined in claim 3 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

10. (withdrawn): A method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering to said mammal a physiologically active amount of a compound as defined in claim 4 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

11. (withdrawn): A method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering to said mammal a physiologically active amount of a compound as defined in claim 5 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

12. (withdrawn): A method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering to said mammal a physiologically active amount of a compound as defined in claim 6 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

13. (withdrawn): A method according to any one of claims 7 to 12 wherein said mammal is a human.

14. (withdrawn): A method for treating a mammal suffering from a disease selected from the group consisting of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn and for the lowering of cardiovascular risk of postmenopausal women and after intake of contraceptives comprising administering to said mammal a physiologically active amount of a compound as defined in claim 1 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

15. (withdrawn): A method for treating a mammal suffering from a disease selected from the group consisting of cardiovascular diseases, stable or unstable

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn and for the lowering of cardiovascular risk of postmenopausal women and after intake of contraceptives comprising administering to said mammal a physiologically active amount of a compound as defined in claim 2 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

16. (withdrawn): A method for treating a mammal suffering from a disease selected from the group consisting of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn and for the lowering of cardiovascular risk of postmenopausal women and after intake of

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

contraceptives comprising administering to said mammal a physiologically active amount of a compound as defined in claim 3 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

17. (withdrawn): A method for treating a mammal suffering from a disease selected from the group consisting of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn and for the lowering of cardiovascular risk of postmenopausal women and after intake of contraceptives comprising administering to said mammal a physiologically active amount of a compound as defined in claim 4 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

18. (withdrawn): A method for treating a mammal suffering from a disease selected from the group consisting of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn and for the lowering of cardiovascular risk of postmenopausal women and after intake of contraceptives comprising administering to said mammal a physiologically active amount of a compound as defined in claim 5 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

19. (withdrawn): A method for treating a mammal suffering from a disease selected from the group consisting of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn and for the lowering of cardiovascular risk of postmenopausal women and after intake of contraceptives comprising administering to said mammal a physiologically active amount of a compound as defined in claim 6 in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

20. (withdrawn): A method according to any one of claims 14 to 19 wherein said mammal is a human.

21. (withdrawn): A method according to only one of claims 14 to 19 wherein the disease is selected from the group consisting of endothelial dysfunction, hypertension, coronary heart disease, stable angina pectoris, diabetes complications and atherosclerosis.

22. (original): A pharmaceutical preparation comprising an effective dose of at least one compound of the formula (I) as defined in claim 1 in any of its stereoisomeric forms or a mixture thereof in any ratio and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

23. (currently amended): A<u>The</u> pharmaceutical preparation according to claim 22, ~~which~~ <u>wherein said</u> pharmaceutical preparation is in the form of a pill, tablet, lacquered tablet, sugar-coated tablet, granule, hard or soft gelatin capsule, aqueous, alcoholic or oily solution, syrup, emulsion or suspension, suppository, solution for injection or infusion, ointment, tincture, spray, transdermal therapeutic systems, nasal spray, aerosol mixture, microcapsule, implant or rod.

24. (new): The compound of formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof according to claim 1, wherein, in the formula (I),

R^5 is chosen from 4-fluorophenyl, 2,2-difluoro-benzo[1,3]dioxol-5-yl, 6-methoxymethyl-pyrid-3-yl, 2-methyl-1H-benzoimidazole-5-yl, and 2-methyl-3H-benzoimidazole-5-yl.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

25. (new): The compound of formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof according to claim 1, wherein, in the formula (I),

each of the groups R^1, R^2, R^3, and R^4 is H and each of the groups A, B, C, and D is CH_2.

26. (new): The compound of formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof according to claim 1, chosen from 4-fluoro-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-benzamide, 2-methyl-3H-benzoimidazole-5-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide, and 2-methyl-1H-benzoimidazole-5-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide.

27. (new): (S)-6-methoxymethyl-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-nicotinamide or a pharmaceutically acceptable salt thereof.

28. (new): (S)-2-methyl-3H-benzoimidazole-5-carboxylic acid (6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-amide or a pharmaceutically acceptable salt thereof.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com